New psoriatic arthritis treatment guideline presented at the 2017 ACR/ARHP Annual Meeting

Authors of the new American College of Rheumatology (ACR) / National Psoriasis Foundation (NPF) treatment guideline for psoriatic arthritis (PsA) will present their draft recommendations during a session at the 2017 ACR/ARHP Annual Meeting this week in San Diego. The guideline includes pharmacologic and non-pharmacologic recommendations for treating adult patients with active psoriatic arthritis. Both the ACR and NPF anticipate the guideline will play an important role in improving outcomes for individuals living with PsA.

The guideline development team used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to develop the recommendations. GRADE uses systematic reviews of the scientific literature available to evaluate and grade the quality of evidence in a particular domain. The evidence reviews are then used to create for or against particular therapy options that range from strong to conditional, depending on the quality of evidence available.

Details of the draft recommendations will be presented on Tuesday, Nov. 7, from 1 - 2 p.m. PT.

The guideline manuscript is currently under peer review and is anticipated to be published in Arthritis & Rheumatology, Arthritis Care & Research and the Journal of Psoriasis and Psoriatic Arthritis in early 2018.


Explore further

New guideline aims to reduce infections in total hip and knee replacement patients

Journal information: Arthritis Care & Research

Citation: New psoriatic arthritis treatment guideline presented at the 2017 ACR/ARHP Annual Meeting (2017, November 5) retrieved 17 July 2019 from https://medicalxpress.com/news/2017-11-psoriatic-arthritis-treatment-guideline-acrarhp.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more